Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kimberly Siu

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Cardiology Research and Practice|October 20, 2012
Long-Term Costs of Ischemic Stroke and Major Bleeding Events among Medicare Patients with Nonvalvular Atrial FibrillationCatherine J Mercaldi, Kimberly Siu, Stephen D Sander, et al.
Journal of the American Academy of Dermatology|June 2, 2005
Etanercept does not effectively treat moderate to severe alopecia areata: an open-label studyBruce E Strober, Kimberly Siu, Andrew F Alexis, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|September 26, 2012
Anticoagulant use, the prevalence of bridging, and relation to length of stay among hospitalized patients with non-valvular atrial fibrillationKaren Smoyer-Tomic, Kimberly Siu, David R Walker, et al.
The Journal of Dermatological Treatment|July 25, 2017
Secukinumab improves scalp pain, itching, scaling and quality of life in patients with moderate-to-severe scalp psoriasisSteven R Feldman, Lawrence Green, Alexa B Kimball, et al.
Immunotherapy|January 9, 2025
Lebrikizumab decreases type 2 inflammatory biomarker levels in patients with asthma: data from randomized phase 3 trials (LAVOLTA I and II)Stanley Szefler, Jonathan Corren, Jonathan I Silverberg, et al.
Journal of the American Academy of Dermatology|August 7, 2017
The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b studyJerry Bagel, Kristina Callis Duffin, Angela Moore, et al.
Circulation. Cardiovascular Quality and Outcomes|August 8, 2013
Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarinMartin Zalesak, Kimberly Siu, Kevin Francis, et al.
Archives of Dermatology|November 18, 2009
Alefacept for severe alopecia areata: a randomized, double-blind, placebo-controlled studyBruce E Strober, Kavita Menon, Amy McMichael, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|February 16, 2013
Readmission among hospitalized patients with nonvalvular atrial fibrillationBarbara H Johnson, Karen E Smoyer-Tomic, Kimberly Siu, et al.
Dermatology and Therapy|July 15, 2025
Lebrikizumab Rapidly Lowers Inflammatory Biomarkers with Clinical Correlations in Moderate-to-Severe Atopic DermatitisEmma Guttman-Yassky, Zhe Sun, Laura Rebeca Mena, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Cardiology Research and Practice|October 20, 2012
Long-Term Costs of Ischemic Stroke and Major Bleeding Events among Medicare Patients with Nonvalvular Atrial FibrillationCatherine J Mercaldi, Kimberly Siu, Stephen D Sander, et al.
Journal of the American Academy of Dermatology|June 2, 2005
Etanercept does not effectively treat moderate to severe alopecia areata: an open-label studyBruce E Strober, Kimberly Siu, Andrew F Alexis, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|September 26, 2012
Anticoagulant use, the prevalence of bridging, and relation to length of stay among hospitalized patients with non-valvular atrial fibrillationKaren Smoyer-Tomic, Kimberly Siu, David R Walker, et al.
The Journal of Dermatological Treatment|July 25, 2017
Secukinumab improves scalp pain, itching, scaling and quality of life in patients with moderate-to-severe scalp psoriasisSteven R Feldman, Lawrence Green, Alexa B Kimball, et al.
Immunotherapy|January 9, 2025
Lebrikizumab decreases type 2 inflammatory biomarker levels in patients with asthma: data from randomized phase 3 trials (LAVOLTA I and II)Stanley Szefler, Jonathan Corren, Jonathan I Silverberg, et al.
Journal of the American Academy of Dermatology|August 7, 2017
The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b studyJerry Bagel, Kristina Callis Duffin, Angela Moore, et al.
Circulation. Cardiovascular Quality and Outcomes|August 8, 2013
Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarinMartin Zalesak, Kimberly Siu, Kevin Francis, et al.
Archives of Dermatology|November 18, 2009
Alefacept for severe alopecia areata: a randomized, double-blind, placebo-controlled studyBruce E Strober, Kavita Menon, Amy McMichael, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|February 16, 2013
Readmission among hospitalized patients with nonvalvular atrial fibrillationBarbara H Johnson, Karen E Smoyer-Tomic, Kimberly Siu, et al.
Dermatology and Therapy|July 15, 2025
Lebrikizumab Rapidly Lowers Inflammatory Biomarkers with Clinical Correlations in Moderate-to-Severe Atopic DermatitisEmma Guttman-Yassky, Zhe Sun, Laura Rebeca Mena, et al.
Pageof 3